Replies to post #80355 on Bioelectronics Corp (BIEL)

[Gramps]

Nonsense.

progress in the UK?

In the UK, sales in Q1 2016 were 10% lower than sales in Q1 2015. Since the "Trial Version" campaign started in 2014, that is not "progress."

If UK sales in Q2 2016 are lower than Q2 2015, I think that puts the debate to rest.

Sales in NZ and Australia will probably add a significant amount to the financials because they rolled out the Trial Version campaign down under. The problem is, the Trial Version is not profitable. This company needs customers to get hooked on the ActiPatch and keep buying them, and the revenue history shows that is not happening.

The new higher-power devices will probably do a better job of healing pain and reducing swelling. But those would require ALL NEW clinicals for FDA clearance. Clinicals cost money.

[llh222]

"In the UK, sales in Q1 2016 were 10% lower than sales in Q1 2015. "

Q1 2015 sales were $503,448, Q1 sales in 2016 were $528,327.

gross profit for Q1 2015 was $220,940, Q1 2016 was $311,871.

Sure looks like things are improving to me.

GLTA

LLH

[seven-up]

You might better do some DD there get darock facts, hummm I guess you do not know who has helped develop the stronger Actipatch or RecoveryRx and trials are already being conducted. geeez really get it...LMAO